RAE-1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma

Adeline R Lam¹,²¶, Nina Le Bert¹¶, Samantha SW Ho¹, Yu J Shen¹,², Li FM Tang¹, Gordon M Xiong¹, John L Croxford¹, Christine X Koo¹,²,³,⁴, Ken J Ishii³,⁴, Shizuo Akira⁵, David H Raulet⁶* and Stephan Gasser¹,²*§

¹Immunology Programme and Department of Microbiology, Centre for Life Sciences, National University of Singapore, 117456, Singapore
²NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, 117597 Singapore
³Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation (NIBIO), 7-6-8 Saito-Asagi, Ibaraki, Osaka, Japan
⁴Laboratory of Vaccine Science, WPI Immunology Frontier Research Center (iFREC), Osaka University, 3-1 Yamadaoka, Suita, Osaka, Japan
⁵WPI Immunology Frontier Research Center (iFREC), Osaka University, 3-1 Yamadaoka, Suita, Osaka, Japan
⁶Department of Molecular and Cell Biology and Cancer Research Laboratory, University of California, Berkeley, CA 94720-3200, USA.

Running Title: Linkage of NKG2D ligands and PRR pathways

Key Words: Innate immunity, NK cells, DNA sensor, DNA damage response, NKG2D.

¶ Authors contributed equally to this study.
* Authors contributed equally to this study.
§ Correspondence and requests for materials should be addressed to S.G. (micsg@nus.edu.sg). Immunology Programme, Department of Microbiology, National University of Singapore, 117456, Singapore.

The authors declare no competing financial interests.
ABSTRACT
The immunoreceptor NKG2D originally identified in natural killer cells recognizes ligands that are upregulated on tumor cells. Expression of NKG2D ligands (NKG2DLs) is activated by the DNA damage response (DDR) which is often activated constitutively in cancer cells, revealing them to natural killer cells as a mechanism of immunosurveillance. Here we report that the induction of retinoic acid early transcript 1 (RAE1) ligands for NKG2D by the DDR relies on a STING-dependent DNA sensor pathway involving the effector molecules TBK1 and IRF3. Cytosolic DNA was detected in lymphoma cell lines which express RAE1 and its occurrence required activation of the DDR. Transfection of DNA into ligand-negative cells was sufficient to induce RAE1 expression. Irf3+/−;Eμ-Myc mice expressed lower levels of RAE1 on tumor cells and showed a reduced survival rate compared to Irf3+/++;Eμ-Myc mice. Taken together, our results suggest that genomic damage in tumor cells leads to activation of STING-dependent DNA sensor pathways, thereby activating RAE1 and enabling tumor immunosurveillance.
INTRODUCTION

The NKG2D system is an arm of innate immune recognition, which is important in the context of both cancer and infection (1-3). Transformed and infected cells increase the expression of NKG2DLs. Engagement of the NKG2D receptor on natural killer (NK) cells and certain T cells stimulates their effector functions, which aid in tumor control (4, 5). Recently, we elucidated a principle mechanism that induces NKG2DLs in cancer cells: the DDR (6). DNA damage upregulates the expression of numerous NKG2DLs, including different retinoic acid early transcript (RAE1) isoforms and mouse UL16-binding protein-like transcript 1 (MULT1) in mouse cells. The DDR molecules ATR (ataxia-telangiectasia and Rad3-related), ATM (ataxia-telangiectasia mutated homolog) and CHK1 (checkpoint kinase-1 homolog) are required for expression of NKG2DLs in response to DNA damage and the constitutive expression of NKG2DLs in some tumor cell lines (6). Additional effector molecules of the DDR required for mouse NKG2DL expression have not been identified.

Optimal immune responses to autologous cells often require the presence of pathogen- and damage-associated molecular patterns. Pattern recognition receptors (PRR) that recognize self-molecules, such as DNA, have been suggested to play a role in cancer (7). Recently identified candidate cytosolic DNA sensors include ZBP1/DAI (Z-DNA binding protein 1) and Rig-I (retinoic acid inducible gene I) (8). Upon recognizing DNA these sensors activate stimulator of interferon genes (STING), TANK-binding kinase-1 (TBK1) and/or the related IKK-related kinase epsilon (IKKe) (9). Activated TBK1 and IKKe directly phosphorylate
interferon regulatory factor-3 (IRF3), which subsequently undergoes dimerization and translocation into the nucleus (10). Nuclear IRF3 induces the expression of target genes including interferon beta (\textit{Infb}) and chemokine C-C motif ligand-5 (\textit{Ccl5}) (11).

Expression of the proto-oncogene \textit{c-MYC} is deregulated in 70% of human cancers. Overexpression of \textit{c-MYC} induces DNA damage and the DDR, which was suggested to act as a barrier against tumor development in premalignant cells (12, 13). In \textit{Eμ-Myc} transgenic mice, \textit{c-Myc} expression is driven by the IgH \textit{Eμ} enhancer leading to precursor-B cell malignancies similar to human Burkitt's lymphoma (14, 15). The tumor suppressors that prevent the development of \textit{c-Myc} expressing premalignant cells have not been well characterized.

In the present study, we show that the DDR leads to the presence of cytosolic DNA and activation of IRF3 in lymphoma cell lines. The induction of RAE1 ligands by the DDR depended on IRF3. Transfection of cells with cytosolic DNA induced the expression of RAE1 molecules. Tumors in \textit{Irf3⁻⁻;Eμ-Myc} mice expressed lower levels of RAE1 and developed lymphoma earlier resulting in a shortened life span when compared to \textit{Irf3⁺⁺;Eμ-Myc} mice. Taken together, these findings link genotoxic stress to cytosolic DNA sensor signaling pathways and the induction of RAE1 in lymphoma cell lines.

MATERIAL and METHODS

\textbf{Cells} BC2 (a kind gift by Dr. Corcoran) and \textit{EμM1} cells were derived from \textit{Eμ-Myc} mice (16). Yac-1 cells were purchased from ATCC. Cells were cultured in
RPMI-1660 medium (Invitrogen) with 10% FCS (Hyclone), 50 μM 2-mercaptoethanol, 100 μM asparagine, 2 mM glutamine (Sigma), 1% pen/strep (Invitrogen) and 1/1000 plasmocin (Invivogen).

EμM1, mouse embryonic fibroblasts (MEFs) and tumor cells in Eμ-Myc mice (C57BL/6) express RAE1βδ and/or RAE1ε. BC2 (C57BL6//129) and Yac-1 (A/Sn) express RAE1α, RAE1β, RAE1γ and RAE1δ.

**Reagents** Aphidicolin, caffeine, CGK733, cytosine β-D-arabinofuranoside hydrochloride (Ara-C), TransFectin, DMSO, Poly G:C, Poly A:U and Poly I:C were purchased from Sigma. KU55933 and VE-821 were obtained from Tocris Bioscience or Axon Medchem. ODN1585, ODN1668 control (ssDNA), and LPS were purchased from Invivogen. DNA was conjugated to Alexa-488 using the Ulysis-labelling kit according to manufacturer’s instructions (Invitrogen).

**Constructs and Transduction** *Irfl*, *Tbk1*, *Ikke*, *Sting*-HA, *Irfl*-Egfp and *Irfl*A7-Egfp were subcloned into the pMSCV2.2-IRES-Gfp vector (gift of Dr. Sha, University of California, Berkeley). Wild-type (WT) and mutant *Sting* fibroblasts were kindly provided by Dr. Vance (University of California, Berkeley). Retroviral supernatants were generated as described in (17). shRNA constructs were cloned into the MSCV/LTRmiR30-PIG vector (Open Biosystems) (See supplementary data).

**Quantitative Real-time RT-PCR** Performed as described in (6).

**Native PAGE Gel Electrophoresis** Performed as described in (18).

**Western Blotting** Whole cell extracts were electrophoresed in 10% or 4-20% SDS-PAGE gels and blotted onto nitrocellulose membranes (BioRad). Antibodies
against IRF3, IRF3pSer396, TBK1, TBK1pSer172, ATM, ATMpSer1981 (Cell Signaling Technology), BCL2L12 (clone E-13, Santa Cruz) and GAPDH (Sigma) and horseradish peroxidase-coupled second stage reagents were used (Thermo). Blots were exposed on X-ray film (Fuji); densitometry analysis was performed using ImageJ-1.46r.

**Flow Cytometry** The following antibodies were used: pan-RAE1, RAE1αβγ, RAE1βδ, RAE1ε (R&D Systems), B220-PerCP, IgM-APC, CD16/CD32, MHC class II (eBioscience), rabbit-anti-phospho-IRF3-Ser396 or rabbit-anti-phospho-TBK1-Ser172 (Cell Signaling Technology) and rat IgG-APC (eBioscience) or rabbit IgG-Alexa-488 (Invitrogen). 1 μg/ml propidium iodide (PI) was added to all stainings and PI negative cells are shown. For intracellular staining, cells were fixed according to the manufacturer’s protocol. Some cells were treated with 2 U/μl λ-phosphatase (NEB) at 37°C for 90 min before staining. Stained cells were analyzed using FACSCalibur and FlowJo. BrdU incorporation analysis were performed as described (19).

**Microscopy** Cells were fixed and stained for DNA according to manufacturer’s instructions (Millipore). A detailed protocol is provided in the supplementary data.

**CD107a Degranulation Assay and In Vitro NK cell Stimulation** Performed as described in (4) and (20).

**Statistical Analyses** Groups were compared using 2-tailed unpaired t-tests (Prism, 5.0c, GraphPad). Survival was represented by Kaplan-Meier curves and statistical analysis was performed with the log rank Mantel-Cox Test.
RESULTS

IRF3 is Necessary for RAE1 Expression in Response to DNA Damage

IRF3 has previously been shown to be activated in response to DNA damage (21, 22). We therefore investigated the role of IRF3 in the expression of NKG2DLs in cells exposed to DNA damaging agents. Phosphorylation of serine 396 (S388 of mouse IRF3) has been shown to be critical for the activation of IRF3 (23). Phosphorylation of IRF3S388 increased after treatment with DDR-inducing agents Ara-C or aphidicolin, although not to the same degree as lipopolysaccharides (LPS), a known inducer of IRF3 (Fig. 1A-B, S1A) (24). The late kinetics of IRF3S388 phosphorylation were similar to kinetics previously observed for DNA damage-induced upregulation of NKG2DLs (6). Notably, treatment of BC2 cells with Ara-C also induced activated IRF3 characterized by nuclear translocation of endogenous IRF3 (Fig. 1C) and overexpressed chimeric IRF3-GFP (Fig. 1D-E) consistent with previous reports (21, 22). No nuclear translocation was observed with a mutant form of IRF3 (IRF3A7-GFP) that is unable to be activated (Fig. 1D-E). Treatment of BC2 cells with Ara-C or aphidicolin induced expression of several IRF3 target genes to a similar or greater extent than Poly I:C, an established IRF3 activator, suggesting that IRF3 is transcriptionally active in response to DNA damage (Fig. 1F-G).

To test if IRF3 is required for DDR-mediated upregulation of NKG2DLs, we transduced BC2 cells with an Irf3-specific shRNA (Fig. S1B). Compared to control shRNA, Irf3-specific shRNA significantly inhibited the upregulation of RAE1 ligands of NKG2D, but not MHC class II, in response to Ara-C (Fig. 1H).
Bimodal expression of RAE1 is likely to reflect specific activation of the DDR in S-phase of the cell cycle. No consistent effects were observed for the NKG2DLs MULT-1 and H60 suggesting that upregulation of MULT-1 in response to DNA damage requires additional signals.

To address if IRF3-induced RAE1 expression renders cells more sensitive to NK cell-mediated lysis, *Irf3*-specific and control shRNA-transduced cells were cultured with IL-2-activated NK cells. BC2 cells transduced with *Irf3*-specific shRNA were less sensitive to NK cell-mediated cytotoxicity in response to Ara-C treatment than control shRNA-transduced BC2 cells (Fig. 1I). The sensitivity of *Irf3*-shRNA-transduced BC2 cells was similar to control shRNA-transduced BC2 cells treated with Ara-C in the presence of NKG2D-blocking antibodies, suggesting that decreased lysis of *Irf3*-shRNA-transduced cells was due to reduced RAE1 expression.

**IRF3 is Required for Constitutive RAE1 Expression in Yac-1 cells**

The DDR is constitutively activated in many tumor cell lines and precancerous lesions (25). In agreement, phosphorylation of IRF3S388 was detected in EμM1 cells and Yac-1 lymphoma cells (Fig. 2A). Endogenous IRF3 (Fig. 2B) and exogenous chimeric IRF3-GFP (Fig. 2C) were partially localized to the nucleus, indicating that a subset of IRF3 is activated in EμM1 and Yac-1 cells. In contrast, IRF3A7 exhibited exclusively cytosolic localization in Yac-1 cells. Inhibition of IRF3 expression in EμM1 and Yac-1 cells by shRNA decreased the expression of IRF3 target genes (Fig. 2D-E), *Raet1* transcripts (Fig. S1C) and RAE1 cell
surface levels (Fig. 2F). Mouse strains were found to express different RAE-1 isoforms and the cell lines used in this study vary in their genetic background (see material and methods) (26). The incomplete reduction of cell surface RAE1 expression by Irf3-specific shRNAs may reflect incomplete turnover of preformed RAE1 or incomplete knockdown of IRF3 (Fig. S1B).

**TBK1 is Necessary for RAE1 Expression in Response to DNA Damage**

IRF3 is activated by the IKK-related serine/threonine kinases TBK1 and IKKε (10). We therefore tested whether TBK1 was phosphorylated in response to DNA damage. Similar to results with IRF3, substantial phosphorylation of TBK1 on serine 172 was detected after 15 hours of treatment with Ara-C or aphidicolin, although the activation was weaker than TBK1 phosphorylation in response to LPS (Fig. 3A-B, S2A). No Ikke expression was detected in BC2 cells (data not shown).

Transduction of BC2 cells with the TBK1 inhibitor Sike caused substantial reduction in RAE1 expression in response to DNA damage (Fig. 3C). Similarly, BC2 cells transduced with Tbk1-specific shRNA expressed less transcripts and RAE1 at the cell surface in response to Ara-C (Fig. 3D, S2B). Tbk1- and Ikke-deficient MEFs failed to upregulate RAE1 in response to Ara-C (Fig. 3E). Genetic reconstitution of Tbk1<sup>-/-</sup>/Ikke<sup>-/-</sup> MEFs with Tbk1 or Ikke was sufficient to induce RAE1 expression on a fraction of cells and to restore the capacity of cells to upregulate RAE1 in response to Ara-C (Fig. 3E). The induction of RAE1 in untreated cells is likely a consequence of overexpression of Tbk1 or Ikke, which has been shown to result in unregulated activation of the pathway (27). In
Linkage of RAE1 expression and PRR pathways Lam et al.

summary, the data suggest that TBK1 is required for induction of RAE1 in response to DNA damage in BC2 cells.

**TBK1 is Required for Constitutive RAE1 Expression**

Similarly to IRF3, constitutive phosphorylation of TBK1S172 was detected in Yac-1 and EμM1 cells (Fig. 3F). Transduction of *Sike* into Yac-1 cells caused reductions in RAE1 levels (Fig. 3G). Expression of a *Tbk1*-specific shRNA in Yac-1 cells decreased the amount of *Raet1* transcripts, and a significant but less complete reduction in RAE1 at the cell surface (Fig. 3H-I). No *Ikke* transcripts were detected in Yac-1 cells (not shown).

**Phosphorylation of IRF3 and TBK1 Depends on the DDR**

Treatment of cells with Ara-C results in DNA breaks and the activation of ATR and ATM (28). To address the role of ATM and ATR in the activation of TBK1 and IRF3, we blocked ATM and ATR function with different chemical inhibitors. Attempts to efficiently block both ATM and ATR by shRNA were not successful. Induction of RAE1 expression in BC2 cells by Ara-C was inhibited by the combined treatment of cells with ATM and ATR inhibitors (Fig. 4A, S3A). Inhibition of ATM and ATR also impaired TBK1 and IRF3 phosphorylation (Fig. 4B-C, S3B) and nuclear localization of chimeric IRF3-GFP (Fig. 1D-E) in Ara-C-treated BC2 cells. The effects of ATM or ATR inhibition on RAE1 expression and phosphorylation of TBK1 and IRF3 were less pronounced suggesting that ATM and ATR act redundantly (Fig. 4A-C).

Inhibition of ATR impaired constitutive RAE1 expression and phosphorylation of TBK1 and IRF3 in Yac-1 cells (Fig. 4D-E, S3C-D). Nuclear
Localization of IRF3-GFP in Yac-1 cells was also suppressed by inhibition of ATR and ATM (Fig. 4F). Thus, activation of TBK1 and IRF3 in Yac-1 cells depends on ATR suggesting that DNA damage, which preferentially activates ATR (29), is present in Yac-1 cells.

Accumulation of Cytosolic DNA Depends on the DDR

Recognition of cytosolic DNA by DNA sensors activates TBK1 and IRF3 (8). To test whether DNA damage leads to appearance of cytosolic DNA, we stained cells with antibodies specific for single-stranded (ss)DNA or double-stranded (ds)DNA (Fig. S4A). The specificity of the DNA-staining was verified by pretreating cells with S1 nuclease to degrade ssDNA or DNase I to digest dsDNA before staining (Fig. S4B-C). All cells were treated with RNase before staining. Strikingly, we found that ssDNA and dsDNA occurred in the cytosol of BC2 cells in response to Ara-C treatment and cytosolic DNA was constitutively present in Yac-1 cells (Fig. 5A-B). To substantiate the presence of DNA in the cytosol of cells, we stained BC2 cells with PicoGreen, a vital dsDNA-specific dye (Fig. S4D). In agreement with the dsDNA-specific antibody stainings, PicoGreen staining showed the presence of cytosolic dsDNA in Yac-1 and Ara-C-treated BC2 cells (Fig. 5C, S5A-B). To exclude the possibility that cytosolic DNA represents mitochondrial DNA, we co-stained cells with mitochondria-specific MitoTracker dye or the mitochondrial marker COX-IV (Fig. 5C, S4-6). As Ara-C disrupted MitoTracker staining, we treated BC2 cells with aphidicolin, an inhibitor of nuclear DNA synthesis that activates the DDR but does not affect replication of mitochondrial DNA (Fig. 5C, S4D) (30).
microscopy data showed that most cytosolic DNA is present outside of mitochondria in Yac-1 and Ara-C-treated BC2 cells (Fig. 5C, S4D, S5).

To test if the DDR influences the occurrence of cytosolic DNA, we pretreated BC2 cells with ATM and/or ATR inhibitors before treatment with Ara-C. Blocking of ATM and ATR prevented appearance of cytosolic DNA in response to Ara-C (Fig. 5A, S6A). Strikingly, cytosolic DNA present in Yac-1 cells disappeared after inhibition of ATR for 14 hours (Fig. 5B, S6B). Inhibition of ATM had a less pronounced effect on the occurrence of cytosolic DNA in agreement with effects observed on RAE1 expression and phosphorylation of IRF3 and TBK1 (Fig. 5A-B). However, the disappearance of cytosolic DNA in response to inhibition of ATM and ATR did not abrogate RAE1 expression in Yac-1 cells suggesting that RAE1 expression is regulated by additional pathways (26). In summary, our data suggest that appearance of cytosolic DNA depends on the DDR and is rapidly turned over.

**Cytosolic DNA Induces RAE1 Expression**

To test whether cytosolic DNA induces RAE1 expression in BC2 cells we transfected cells with Alexa-488-labelled plasmid DNA, genomic DNA or ssDNA. We were unable to purify sufficient quantities of cytosolic DNA to determine whether cytosolic DNA present in Ara-C-treated BC2 cells directly induces RAE1 expression. Alexa-488-positive BC2 cells upregulated expression of RAE1, although to a lesser degree than Ara-C-treated cells (Fig. 6A).

The presence of DNA in the cytosol activates STING-dependent DNA sensors leading to the activation of TBK1 and IRF3 (8). We therefore tested
whether STING is necessary for RAE1 expression in cells exposed to genotoxic stress. MEFs harboring a loss-of-function *Sting* mutation failed to upregulate RAE1 in response to Ara-C (Fig. 6B). Reconstitution of *Sting* expression resulted in restored inducibility of RAE1 in the cells. Furthermore, RAE1 induction by Ara-C was impaired in BC2 cells expressing a *Sting*-specific shRNA (Fig. 6C) and *Sting* inhibition in Yac-1 cells resulted in reduced constitutive RAE1 expression (Fig. 6D).

Next, we tested the requirement in RAE1 induction for one candidate STING-dependent DNA sensor, ZBP/DAI, that activates IRF3 (8). Knockdown of *Zbp1/Dai* partly inhibited the upregulation of RAE1αβγ in response to Ara-C, but had little effect on RAE1βδ (Fig. 6C). In contrast, knockdown of ZBP1/DAI modestly inhibited RAE1βδ but not RAE1αβγ expression in Yac-1 cells (Fig. 6D). Inhibition of Rig-I, a RNA sensor that may indirectly mediate responses to cytosolic DNA, had no effect on RAE1 expression in BC2 or Yac-1 cells (Fig. 6C-D). Hence, DNA sensors other than ZBP1/DAI are likely to participate in inducing RAE1 expression in response to DNA damage, in line with other evidence suggesting the existence of DNA sensors that act redundantly (31). Taken together, these data suggest that cytosolic DNA sensor pathways regulate RAE1 expression in cells exposed to DNA damage.

**IRF3 Regulates RAE1 Expression in B-Cell Lymphomas of Eμ-Myc mice**

To address if IRF3 regulates RAE1 expression in lymphomas, *Irft3*-deficient mice were bred to mice overexpressing c-Myc under the control of Ig heavy chain enhancer region (Eμ), analogous to human Burkitt lymphoma (32). Spontaneous
B220^{low} B-cell lymphomas develop by 15-20 weeks of age and the progression of lymphomas is accelerated in NKG2D^{-/-};E{\mu}-Myc mice (4, 33). Tumor cells in E{\mu}-Myc mice express phosphorylated ATM (ATM{\text{pS1981}}) (Fig. 7A) (34). Staining of tumor cells with a dsDNA-specific antibody revealed the presence of cytosolic dsDNA in B220^{low} tumor cells, but not normal B220^{+} B-cells (Fig. 7B). The accumulation of cytosolic DNA was strictly dependent on the DDR as administration of the ATM inhibitor KU55933 resulted in reduced levels of cytosolic dsDNA (Fig. 7C). \textit{Irf3^{+/-};E{\mu}-Myc} mice (median survival=62 days) experienced a significantly reduced survival rate compared to \textit{Irf3^{+/+};E{\mu}-Myc} mice (median survival=116 days) (Fig. 7D). We were not able to generate \textit{Irf3^{-/-};E{\mu}-Myc} mice because \textit{Irf3^{+/-};E{\mu}-Myc} mice failed to breed. Heterozygosity of \textit{Irf3} in E{\mu}-Myc mice resulted in 2.5-fold decrease of IRF3 levels and reduced expression of IRF3 target genes in splenic B-cell lymphomas when compared to \textit{Irf3^{+/+};E{\mu}-Myc} mice, suggesting that cytosolic DNA in lymphomas activates IRF3 (Fig. 7A, E). Importantly, reduced levels of IRF3 in lymphomas impaired RAE1{\varepsilon} expression, the only RAE1 family member detected in E{\mu}-Myc tumor cells (Fig. 7F) (35).

The null mutation introduced into the \textit{Irf3} allele also resulted in functional inactivation of the neighboring \textit{Bcl2l12} gene, which promotes or suppresses tumorigenesis depending on the cellular context (36, 37). However, heterozygosity of the gene-targeted locus did not result in reduced BCL2L12 levels or changes in the rate of apoptosis or proliferation of lymphomas (Fig. 7A, S7A-B). Overexpression of \textit{Bcl2l12} in BC2 and E{\mu}M1 cells, two cell lines derived
from Eμ-Myc mice, had no effect on RAE1 expression, proliferation or apoptosis (Fig. 7G, S7C-D). We previously found that NK cells and T-cells contribute to immunosurveillance in Eμ-Myc mice (34). However, Irf3-deficiency had no impact on NK- and T-cell numbers or NK cell activity (Fig. 7H) (38). In summary, our data suggest that RAE1 ligands are regulated by IRF3 in lymphomas of Eμ-Myc mice. Interestingly, IRF3 is likely to have additional functions in immunosurveillance as NKG2D-deficiency increases the tumor load of Eμ-Myc mice, but has no impact on survival (4).

DISCUSSION
Our previous results provided evidence that the DDR activates immune responses by inducing NKG2DLs (6). Here we show that cytosolic DNA contributes to the induction of RAE1 expression in lymphoma cells in response to DNA damage for the following reasons: 1) Inhibition of the DDR impaired the induction of cytosolic DNA and RAE1 molecules; 2) Transfection of DNA into cells upregulated RAE1 expression; 3) Inhibition of STING, TBK1 or IRF3 impaired RAE1 expression; 4) TBK1 and IRF3 were activated in response to DNA damage in a DDR-dependent manner, and 5) Overexpression of TBK1 or IKKe induced RAE1 expression.

Linking the DDR to STING-initiated pathways is of interest immunologically, because STING is a critical component of a major pathway common to receptors that detect cytosolic DNA and RNA of pathogens (8). Previous studies provided indications that the DDR induces phosphorylation of
IRF3 and that certain TLR agonists induce *Raet1* gene expression in peritoneal macrophages (39), but the linkage of these pathways had not been explored. Much remains to be determined concerning the relation of the DDR and STING pathways. We observed less phosphorylation of IRF3 in response to DNA damage when compared to LPS suggesting that IRF3 translocation and transcriptional activity is differentially regulated in response to DNA damage. Consistent with this possibility, Noyce *et al.* reported that no minimal post-translational modification of IRF3 correlated with its transcriptional activity (40). Of interest was that DNA damage consistently led to lower induction of IFN than Poly I:C. The reduced induction likely reflects the fact that the DDR failed to induce IRF7 activation, which is necessary for efficient transcription of IFN genes.

Cytosolic DNA has been shown to be present in cells upon infection or the uptake of apoptotic cells (8). Our data show the presence of cytosolic DNA in uninfected lymphoma cell lines. An intriguing question is where cytosolic DNA originates from and the mechanism leading to cytosolic DNA in tumor cells. DNA damage is known to induce transcription of retroelements, including transposases, derived from functional endogenous retrovirus present in the genome (41). Alternatively, cytosolic DNA could be generated during DDR-dependent DNA-repair that can result in deletion of genomic DNA.

An important question is the nature of the DNA sensor recognizing the cytosolic DNA. The induction of RAE1 by Ara-C partially relied on ZBP1/DAI. ZBP1/DAI is a candidate sensor that is reported to activate TBK1/IRF3 (18). However, additional TBK1-activating DNA sensors exist since MEFs from *Zbp1−/−*
deficient mice mount a normal type-I IFN response to DNA (18, 31). These sensors may be required for constitutive RAE1 expression in Yac-1 cells. Hence, unidentified DNA sensors may play a predominant role in YAC-1 cells, or may function redundantly with ZBP1/DAI, in the induction of RAE1.

NKG2D plays an important role in immunosurveillance of tumors in Eμ-Myc mice (4, 42). The accelerated development of lymphoma in Irf3/Bcl2l12+/−;Eμ-Myc mice when compared to NKG2D-deficient mice suggests that IRF3 induces the expression of molecules other than RAE1 ligands important for immunosurveillance or suppression of tumorigenesis. IRF3 and BCL2L12 are known to induce genes implicated in apoptosis (11). However, we observed no differences in the rates of apoptosis or proliferation comparing wild-type and heterozygous tumor cells suggesting that accelerated tumorigenesis of Irf3/Bcl2l12+/−;Eμ-Myc mice is not due to effects of IRF3 or BCL2L12 on apoptosis or proliferation. In summary our data suggest that tumorigenesis leads to accumulation of cytosolic DNA and subsequent activation of an anti-tumor immune response that may partially depend on NKG2D.

ACKNOWLEDGMENTS

This work was supported by BMRC grant 07/1/21/19/513, NRF grant HUJ-CREATE-Cellular and Molecular Mechanisms of Inflammation and by grants from the US National Institutes of Health to DHR.

REFERENCES
FIGURE LEGENDS

Figure 1. IRF3 is activated and necessary for optimal induction of RAE1 ligands for NKG2D in response to DNA damage. (A) Phosphorylation of IRF3-S388 in BC2 cells treated with 10 μM Ara-C, 4 μM aphidicolin, 1 μg/ml ODN1585 (red line) or DMSO (blue line) was analyzed by intracellular flow cytometry at indicated time points. Filled histograms: isotype staining of Ara-C-treated cells. Mean fluorescence intensity (MFI) ±SD are shown. (B) Phosphorylation of IRF3-S388 after 16 hrs of 10 μM Ara-C or DMSO treatment was analyzed by western-blotting. Raw 264.7 cells were treated with LPS for 4 hrs. (C) Nuclear translocalization of endogenous IRF3 (red) in BC2 cells treated with 10 μM Ara-C for 16 hrs and stained for IRF3 in presence of DAPI (blue). (D-E) BC2 cells expressing IRF3-Gfp or IRF3A7-Gfp were treated with 10 μM Ara-C, 10 μg/ml Poly I:C or DMSO for 16 hrs. Some cells were pretreated with 10 μM of the ATM/ATR-specific inhibitor CGK733. Localization of IRF3 in DAPI-stained cells was analyzed by fluorescent microscopy (D). Quantification of BC2 cells with nuclear (white bar; >90% nuclear), partial nuclear (grey bar; 10-90% nuclear) and cytosolic (black bar; <10% nuclear) localization of IRF3 (E). (F) BC2 cells were treated with DMSO (white bar), 10 μM Ara-C (light-grey bar), 4 μM aphidicolin (grey bar), 1 μg/ml Poly I:C for 20 hrs (black bar), or 1 μg/ml Poly I:C for 4 hrs (dark-grey bar). Relative mRNA levels of IRF3 target genes were measured by qRT-PCR. Means ±SD of 3 independent experiments normalized to DMSO-treated cells are shown. (G) Levels of IFN-β in supernatants of 0.75 x 10^6 BC2 cells/ml treated with DMSO, 10 μM Ara-C or 1 μg/ml Poly I:C for 24 hrs were determined by ELISA. *p<0.05. (H) RAE1 expression in Irf3-specific (red line) or control (blue line) shRNA-transduced BC2 cells, which were cultured for 5 days in puromycin before treatment with 10 μM Ara-C for 16 hrs. DMSO-treated Irf3 (dashed line) or control (dotted line) shRNA-transduced cells are also shown. Filled histograms: isotype staining of Ara-C-treated cells. MFI ±SD are indicated. (I) IL-2-activated NK cells were co-cultured with Irf3-specific (circles) or control shRNA-transduced (squares) BC2 cells in presence of NKG2D-blocking antibodies (open symbols) or IgG2a isotype control antibodies (filled symbols)
and treated with 10 μM Ara-C (red) or DMSO (black) for 16 hrs. The effector (E) to target (T) ratio is indicated. Results ±SD of 3 independent experiments are shown.

**Figure 2. IRF3 is necessary for constitutive RAE1 expression in Yac-1 and EμM1 cells.** (A) Expression of IRF3pS388 in Yac-1 and EμM1 was detected by intracellular flow cytometry (blue line). Some cells were pretreated with λ-phosphatase before staining (red line). Filled histogram: isotype-staining of Yac-1 cells. MFI ±SD are indicated. (B) Yac-1 and EμM1 cells were stained for endogenous IRF3 (red) and DAPI (blue). (C) IRF3-Gfp or IRF3A7-Gfp-transduced Yac-1 cells were examined by confocal microscopy for GFP expression in presence of DAPI (blue). (D-E) Relative transcript levels of IRF3 target genes in *Irf3*-specific (grey and black bars) or control shRNAs (white bar)-transduced Yac-1 (D) and EμM1 (E) cells were analyzed by qRT-PCR. Means ±SD of 3 independent experiments normalized to control shRNA-transduced cells are shown. *p<0.05, **p<0.01. (F) RAE1 expression in *Irf3*-specific (red line) or control (blue line) shRNA-transduced Yac-1 or EμM1 cells 5 days after selection in puromycin. Isotype control staining of *Irf3*- (dotted line) or control shRNA- (filled-histogram) transduced cells is shown. MFI ±SD are indicated.

**Figure 3. Expression of RAE1 depends on TBK1.** (A) Levels of TBK1S172 phosphorylation in BC2 cells treated as indicated in Fig. 1A (bold line) or DMSO (fine line). Filled histograms: isotype staining of DMSO-treated cells. (B) Immunoblot analysis of TBK1S172 phosphorylation in 10 μM Ara-C (14 hrs) or DMSO-treated BC2 cells. Raw 264.7 cells were treated with LPS for 4 hrs for comparison. (C) BC2 cells were transduced with retroviral vectors encoding *Sike* (bold line) or control vector (fine line). 10 days post-transduction BC2 cells were treated with 10 μM Ara-C or DMSO for 16 hrs and stained for RAE1. Isotype staining of control- (dashed line) or *Sike* (filled histogram) transduced cells is shown. (D) RAE1 expression in *Tbk1*-specific (bold lines) or control (fine line) shRNA-transduced BC2 cells treated with 10 μM Ara-C for 16 hrs. *Tbk1*-specific (dashed line) or control (dotted line) shRNA-transduced cells treated with DMSO.
were also stained for RAE1 expression. Filled histogram: isotype control of Ara-
C-treated cells. (E) Tbk1−/−Ikke−/− MEFs were transduced with retroviral vectors
encoding Tbk1, Ikkε or with empty vector. 8 days after selection, cells were
treated with 10 μM Ara-C for 16 hrs (bold line) or DMSO (fine line) and analyzed
for the expression of indicated NKG2DLs. Isotype stainings of DMSO (filled
histogram) or Ara-C-treated (dashed line) are shown. (F) Levels of TBK1S172
phosphorylation in Yac-1 cells were analyzed by intracellular flow cytometry (fine
line). Some cells were pretreated with λ-phosphatase before staining (bold line).
Filled histogram: isotype-staining of Yac-1 cells. (G) RAE1 expression in Sike-
encoding vector (bold line) or empty vector-transduced Yac-1 cells (fine line) 10
days post-transduction. Filled histogram: isotype stainings of Sike-expressing
cells. Dashed line: isotype control of empty vector-transduced cells. (H) Levels of
Raet1 transcripts were determined by qRT-PCR in Tbk1-specific (open bar) or
control (filled bar) shRNA-transduced Yac-1 cells 5 days post-transduction. Data
represent means ±SD for 3 independent experiments. (I) RAE1 expression in
Tbk1-specific (bold line) or control (fine line) shRNA-transduced Yac-1 cells.
Isotype staining of Tbk1-specific (dashed line) and control (filled histogram)
shRNA-transduced cells is shown. MFI ±SD are indicated.

Figure 4. ATR-dependent activation of TBK1 and IRF3 in response to DNA
damage. (A-C) Analysis of RAE1 expression (A), phosphorylation of TBK1S172
(B) and IRF3S388 (C) in 10 μM Ara-C-treated (16 hrs) BC2 cells pretreated with
10 μM of the ATM inhibitor KU55933, the ATR inhibitor VE-821, KU55933+VE-
821 (red line) or DMSO (blue line). Control cells were pretreated with the same
inhibitors (dashed line) or DMSO (fine line) before DMSO treatment. Filled
histograms: isotype control staining. MFI ±SD are indicated. (D-E) Yac-1 cells
treated with ATM and/or ATR-specific inhibitors (red line) or DMSO (blue line) for
16 hrs as indicated above and stained for RAE1 (D), TBK1pS172 (left panel) and
IRF3pS388 (right panel). Filled histograms: isotype control staining. MFI ±SD are
indicated (E). (F) IRF3-Gfp or IRF3A7-Gfp-transduced Yac-1 cells were treated
with 10 μM of KU55933+VE-821 or DMSO for 14 hrs. IRF3 expression and DAPI
(blue) staining was analyzed by fluorescent microscopy.
Figure 5. DNA damage leads to the appearance of cytosolic DNA. (A) Staining of BC2 cells for presence of ssDNA (left columns) or dsDNA (right columns) in presence of DAPI (1st and 3rd column). BC2 cells were pretreated with 10 μM of the ATM inhibitor KU55933, the ATR inhibitor VE-821, KU55933+VE-821, or DMSO followed by treatment with DMSO or 10 μM Ara-C for 14 hrs. BC2 cells were treated with RNase and stained with ssDNA- or dsDNA-specific antibodies (red) and DAPI (blue). (B) Yac-1 cells were treated with 10 μM KU55933, VE-821, KU55933+VE-821, or DMSO for 14 hrs and stained as outlined in (A). (C) DMSO (left panel) or 4 μM aphidicolin-treated (middle panel; 14 hrs) BC2 cells and Yac-1 cells (right panel) were incubated with the dsDNA-specific-dye PicoGreen (green) for 1 hr and MitoTracker dye (red) for 15 min. Z-stack images were acquired by confocal microscopy and analyzed using Imaris software to generate iso-surface plots.

Figure 6. RAE1 expression is induced by cytosolic DNA and depends on STING. (A) BC2 cells were transfected with 4 μg Alexa-488-labelled MSCV-IRES-Gfp plasmid DNA, C57BL/6 genomic DNA or ssDNA. Some cells were treated with 10 μM Ara-C or DMSO. 16 hrs later, BC2 cells were stained for indicated NKG2DLs and analyzed by flow cytometry. Bold line: Ara-C-treated or Alexa-488+ cells; dashed line: Alexa-488- or DMSO-treated cells; fine line: isotype staining of Ara-C-treated or Alexa-488+ cells; dotted line: isotype staining of Alexa-488- cells; filled histograms: isotype staining of DMSO-treated cells. (B) MEFs expressing non-functional or WT Sting were transduced with retroviral vectors encoding Sting or empty vector. 8 days after selection, cells were treated with 10 μM Ara-C for 16 hrs (bold line) or DMSO (fine line) and stained for indicated NKG2DLs. Isotype stainings of DMSO (filled histogram) or Ara-C-treated cells (dashed line) are shown. (C) Sting-, Zbp1/Dai- and Rig-I-specific (bold line) or control shRNAs-transduced (fine line) BC2 cells were treated with 10 μM Ara-C for 16 hrs. Gene-specific (dashed line) or control shRNA-transduced (dotted line) BC2 cells were also treated with DMSO for 16 hrs. NKG2DL expression was analyzed by flow cytometry. Filled histograms: isotype staining of Ara-treated cells. (D) Sting-, Zbp1/Dai-, and Rig-I-specific (bold lines)
or control shRNA-transduced (fine line) Yac-1 cells were stained for NKG2DL expression. Isotype staining of gene-specific (dashed line) or control shRNA (filled histogram)-transduced Yac-1 cells is shown. MFI ±SD are indicated.

**Figure 7. RAE1 Expression in Myc-Driven Lymphomas Depends on IRF3.**

(A) Immunoblot analysis of splenic B cell lymphomas (>78% purity) from Irf3+/−;Eμ-Myc, Irf3+/−;Eμ-Myc, Irf3+/−;WT, Irf3+/−;WT and Irf−/−;WT probed with antibodies for IRF3, BCL2L12, ATM, ATMpS1981 and GAPDH (left panel). Densitometry analysis of immunoblots showing mean ±SD from 3 mice normalized to GAPDH levels; **p < 0.01. (B) B220+ (green) cells of WT and Eμ-Myc mice were stained for dsDNA (red) in presence of DAPI (blue) on 54 days of age. (C) Eμ-Myc mice were injected i.p. with 5 mg/kg KU55933 (n=3) or vehicle (n=3) on 34 and 36 days of age and stained for dsDNA (red), B220 (green) and DAPI (blue) on 38 days of age. (D) Irf3+/−;Eμ-Myc mice (thick) exhibit decreased survival compared to Irf3+/−;Eμ-Myc (thin line) or non-transgenic (dashed line) or Irf3−/− mice (dotted line). Kaplan-Meier-analysis of survival of Irf3+/−;Eμ-Myc mice (n=25; median survival=116 days), Irf3+/−;Eμ-Myc mice (n=17; median survival=62 days) and Irf3+/+ or Irf3−/− mice (n=25; median survival= >250 days). p<0.0001 by Log-Rank-Test or by Gehan-Breslow-Wilcoxon-Test. (E) Relative mRNA levels of indicated IRF3 target genes in purified tumor cells of Irf3+/−;Eμ-myc and Irf3+/−;Eμ-Myc mice were measured by qRT-PCR. (F) RAE1ε expression in tumor cells of three Irf3+/−;Eμ-Myc mice. B220low cells in blood of moribund Irf3+/−;Eμ-Myc, Irf3+/−;Eμ-Myc and C57BL/6 mice (bold line) were stained for the indicated NKG2D ligand expression. Filled histogram: isotype staining of B220low tumors. (G) Bcl2l12-IRES-Gfp (red line) or IRES-Gfp-transduced (blue line) BC2 (left panel) or EμM1 (right panel) cells were stained for the indicated NKG2DL ligand expression. Filled histograms: isotype staining of B220low tumors. Fine line: isotype staining of IRES-Gfp-transduced cells. Filled histograms: Isotype staining of untransduced cells. (H) IL-2–activated NK cells derived from Irf3+/−;Eμ-Myc (white squares, n=8) or Irf3+/−;Eμ-Myc (black circles, n=7) mice were co-cultured with Yac-1 cells at an effector to target ratio of 3:1. After 4 hrs, the percentage of CD107a and IFN-γ-expressing NK1.1+CD3− cells was
determined by flow cytometry (left and middle panel). Freshly isolated splenocytes of \textit{Irf3}^{+/+};E\textsigma-Myc \textit{(white squares, \textit{n}=4)} and \textit{Irf3}^{+/+};E\textsigma-Myc \textit{(black circles, \textit{n}=4)} mice were stimulated \textit{in vitro} for 5 hrs on plates coated with NKG2D-specific antibodies (MI-6, 10 \textmu g/ml), or isotype control (10 \textmu g/ml) before staining and analysis. Intracellular IFN-\gamma was detected by flow cytometry gated on NK1.1^{+}CD3^{-} cells \textit{(right panel)}. Error bar denotes standard error of mean.
Fig. 2

A) Yac-1 and EμM1

IRF3pS388

6±1 38±3

6±3 42±6

B) Yac-1 and EμM1

IRF3/DAPI

C) Yac-1 and EμM1

IRF3-GFP/DAPI

IRF3A7-GFP/DAPI

D) Yac-1

Fold reduction

E) EμM1

Fold reduction

F) Yac-1

RAE1αβγ 183 ±52

RAE1βδ 471 ±39

IRF3 shRNA

RAE1ε 103 ±19

Ctrl shRNA

17 ±4

200 ±26
Fig. 3
Fig. 4
**Fig. 7**

A. Western blot analysis showing relative intensities of IRF3, BCL2L12, ATM, ATMps1981, and GAPDH.

B. Immunofluorescence images of dsDNA/B220/DAPI and dsDNA in WT d54 and Eμ-Myc d54.

C. Immunofluorescence images of Vehicle, KU55933, and Eμ-Myc in dsDNA/B220/DAPI and dsDNA.

D. Kaplan-Meier survival curve showing % survival of Irf3+/+ and Irf3−/− in Eμ-Myc mice. The p-value is <0.0001.

E. Relative mRNA levels of various genes in WT, Irf3−/−, Eμ-Myc, and Eμ-Myc treated with KU55933.

F. Flow cytometry analysis showing %CD107a+ and %IFNγ+ in NK cells from BC2 and EμM1 with RAE1αβγ, RAE1βδ, RAE1βδ, and RAE1ε.

G. Hotspots of CD107a+ and IFNγ+ in NK cells from BC2 and EμM1 with Ctrl and NKG2D.
RAE-1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma

Adeline R. Lam, Nina Le Bert, Samantha S.W. Ho, et al.

Cancer Res  Published OnlineFirst March 3, 2014.

Updated version  Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-1703

Supplementary Material  Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/03/04/0008-5472.CAN-13-1703.DC1

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.